10.28
-0.35 (-3.29%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Design Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.6 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.44 |
|
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 36.09% |
| 机构持股比例 | 61.09% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Logos Global Management Lp | 30 Jun 2026 | 3,000,000 |
| Frazier Life Sciences Management, L.P. | 30 Jun 2026 | 1,809,854 |
| Caption Management, Llc | 30 Jun 2026 | 1,118,098 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 865,135 |
该时间范围内无数据。
该时间范围内无数据。
投资组合